Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells

Alessandro Genna, Stefanie Lapetina, Nikola Lukic, Shams Twafra, Tomer Meirson, Ved P. Sharma, John S. Condeelis, Hava Gil-Henn

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

The nonreceptor tyrosine kinase Pyk2 is highly expressed in invasive breast cancer, but the mechanism by which it potentiates tumor cell invasiveness is unclear at present. Using high-throughput protein array screening and bioinformatic analysis, we identified cortactin as a novel substrate and interactor of proline-rich tyrosine kinase 2 (Pyk2). Pyk2 colocalizes with cortactin to invadopodia of invasive breast cancer cells, where it mediates epidermal growth factor-induced cortactin tyrosine phosphorylation both directly and indirectly via Src-mediated Abl-related gene (Arg) activation, leading to actin polymerization in invadopodia, extracellular matrix degradation, and tumor cell invasion. Both Pyk2 and the closely related focal adhesion kinase (FAK) regulate tumor cell invasion, albeit via distinct mechanisms. Although Pyk2 regulates tumor cell invasion by controlling invadopodium-mediated functions, FAK controls invasiveness of tumor cells by regulating focal adhesion-mediated motility. Collectively, our findings identify Pyk2 as a unique mediator of invadopodium formation and function and also provide a novel insight into the mechanisms by which Pyk2 mediates tumor cell invasion.

Original languageEnglish
Pages (from-to)375-395
Number of pages21
JournalJournal of Cell Biology
Volume217
Issue number1
DOIs
StatePublished - 2 Jan 2018

Bibliographical note

Publisher Copyright:
© 2018 Genna et al.

Funding

This work was funded by the Israel Science Foundation (grants 996/12 and 1749/12), the Israel Cancer Research Fund (grant 12-709-RCDA), the Israel Cancer Association (grant 20141043), a European Commission Marie Curie Career Integration Grant (grant 321556), the Helmsley Charitable Trust Fund (grant 2012PG-ISL013 to H. Gil-Henn), and the National Institutes of Health (grant CA150344 to J.S. Condeelis). The authors declare no competing financial interests.

FundersFunder number
National Institutes of Health
National Cancer InstituteR01CA150344
Israel Cancer Research Fund12-709-RCDA
Leona M. and Harry B. Helmsley Charitable Trust2012PG-ISL013
European Commission321556
Israel Cancer Association20141043
Israel Science Foundation1749/12, 996/12

    Fingerprint

    Dive into the research topics of 'Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells'. Together they form a unique fingerprint.

    Cite this